obsessive-compulsive disorder
Conditions
Interventions
Patients with obsessive-compulsive disorder treated with fluvoxamine. The initial daily dose is 50 mg and gradually increased up to 300 mg given in 2 divided doses.
healthy volunteers
Sponsors
Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine,
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The inclusion criteria for patients were: (1) patients with obsessive compulsive disorder treated at the Kyoto Prefectural University of Medicine Hospital, Kyoto, Japan; (2) not having current or past diagnosis of psychiatric diseases and significant physical disease except the major depressive disorder; (3) the ability to give written, informed consent after receiving a complete description of the study. The inclusion criteria for healthy controls were: (1) healthy controls matched for age and sex participated in this study without current or past diagnosis of psychiatric diseases and significant physical disease except the major depressive disorder: (2) the ability to give written, informed consent after receiving a complete description of the study.
Exclusion criteria
Exclusion criteria: The exclusion criteria for patients and healthy controls were: (1) cardiac pacemakers or other metallic implants or artifacts; (2) other factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The strength of the functional and structural connectivity between the orbitofrontal cortex and the ventral striatum evaluated 12 weeks after starting fluvoxamines | — |
Countries
Japan
Contacts
Public ContactTakashi Nakamae
Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Department of Psychiatry
Outcome results
None listed